{"name":"Immusoft of CA, Inc.","slug":"immusoft-of-ca-inc","ticker":"","exchange":"","domain":"immusoftofca.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxPLVJPZUxScDNtSnZBb2hjck5EaEFjNWt3bEJLb2dmalRkelQwenRFVHVNLVBYMmJ6bER2R1N4Zm1OSlE0LXhtMjNoZ2FPVGtBUFM3NU43cHdpVWRoNEZaSW5iUTBKLXdWVXZHc0ROc1V5VTd2eTdjQVN5Vlk4RThIQlp1YmJMMWJQOVlIeU9DNFNsdi1za0RwdmxlR2gwcV9heC1LOHVYTzhSRDNqTTJyNUhWVHVCaUF2c3EtLXZQTjdvTjNUN0pRQ2hiVTlXME9RUVpQUThZVUhTMDl6TG9rZ0k5LWYzblFINktrRzFvQUVZMGZ4bUc2SGZ3?oc=5","date":"2026-03-30","type":"pipeline","source":"globenewswire.com","summary":"Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine - globenewswire.com","headline":"Immusoft Awarded $15 Million in Funding from the California Institute for Regenerative Medicine","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9gFBVV95cUxNVWdYUElpM3dYdmlYQ0sxVTF1YW9rYVMxVnVnRDlZWE1CM2VzUHZrQVl2b3NlNlR0bkp4MGdPSjNoZlFMQzkyNHdCaGxLYnVKS2tBSUd4Q1A5N1JhNVpELVl3SzVkVjhaUlozWTM0VVNaTHJNSFRGbWtBRlhfbDR6SmtVNEFGMlpWanFndVB2Y2lEVUdDSDlxYWFsVnFqZjdCWnk5U3ZxLUFHSkIzVjlSQnJvdWhja01qci1LTTlaY3BOSVBzMlV1bXJ0SHU5NnFrWWtZck1SRENjOS1PUXFhVEpKS2dBT0V5YlZGQVR0dDhtTVhMN0E?oc=5","date":"2026-01-26","type":"regulatory","source":"PR Newswire","summary":"Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II - PR Newswire","headline":"Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9AFBVV95cUxQX0dpVzR4elJkUFVObmFuQ0NWSHlObEwybTVSTDBnZk1ncXhub0g5Z3VVYWw5TVR0RkkzT2VaTjQ2dXFaZ0dkNlg1X1lpbEZtYzFOMEhvTEVZRWVoYmo1dlR5WXdxdjZBSHBqOWFGYVRPNFMwQWVSa1pIR2pQX0lLQm9jWkpNM3NVNzRJYy1NcVZBMFN6dTBJTExnaERxaEpVUWlkd2l1U1poeXBWQWlLdVBnc3JwQWdlY2RwTzVZM2h6eW81OUFfd2llX21QRTU5Z1duWE02T0I4SmctV1ZUbFF6M3FHbDMteFRHc20zZ1NhRnFP?oc=5","date":"2025-12-15","type":"regulatory","source":"PR Newswire","summary":"Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease - PR Newswire","headline":"Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAJBVV95cUxNaW9weExqd25IZC1NSTVZU2kzRE5MSjBnelV2bTNjWkk1aEZ2X3RTaVJvTWJmMm1XWHUwZEdpX2FHUnRkSHE2Ulc5cW94MjR3aFZGak5acG4wZ1pwaFA4SGUxdXlDTm9aUFpjWDBLSl9DMWRRU1ZIMjZLOUxIZFQwaWFGY3BtNklBOERtYXBBbVZ2bmdYa0Z5N21RWVlhSDh3Sjg2T3BIVktWU3VzcmNGb2xFcEVpTnB4ZmR6dHNCN2VRRjBmcVB3M2pMVnRwMjA1TmZZdnFULV83cFpUMnNTeVZ6UVhJUTVCYnBmTFhfYUh1b0tCcnEtU3hDMlo4bXFoNlB4U2dmZEZGcGtR?oc=5","date":"2025-10-07","type":"pipeline","source":"PR Newswire","summary":"In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for MPS I - PR Newswire","headline":"In a Major Breakthrough for Cell and Gene Therapy, Immusoft Has Re-dosed a Patient with ISP-001 in Its Lead Program for ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwJBVV95cUxNV2xYd2tFY0JrNXctOVVCLThVVzhqNHBVb1ZzWnhUeVJRYm5tV0htSUJBZlBST3ZKRWFseDFodUpIUFNGSUhfTjVDSVg5WGpwWXJUT1dZUXdZSnAwQWU5dlFiY0djUWpsdHpUYmNTTkhsc2NBVkdwR2lHb3duaW8xYkRZZ1pUcWZGdGxZb2g1TWFNc29abjdqTHh2Rl8wNVJ6YjYzdVlLRjRyZThicXU0UXZvTUYtWldEMTNuRGE4b1gweTVtTURaenZpQlhVNnFHRlprb3ZETXRtMkktLV9WVlY0OEFrekQyUnNveF9iTFNPZmVfZTVJanZJaVhYNVQ4ZzJRbUVpSHllSy1rbW96dnQyc0MwaFNKTUtN?oc=5","date":"2025-05-13","type":"trial","source":"PR Newswire","summary":"Immusoft to Present Data at ASGCT 2025, Demonstrating Positive Results from the World's First Engineered B Cell in a Human Clinical Trial - PR Newswire","headline":"Immusoft to Present Data at ASGCT 2025, Demonstrating Positive Results from the World's First Engineered B Cell in a Hum","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilgJBVV95cUxPcmQ2NWlZQnlDOXJtNElqaDV4NlpEUTZkTnlMbkRrcE5GSW93Yzc5VWVUQ2dsZlhKWGtVdHYyUVZxeDdLY2dHVGdoREJBOXV3QkdMcFlZUVZ6OE5kM2ZpckFXT1F5WmE0UVVVNmlnbERMWkY1N0lSZEx5bjJqdkU1ak5LdUFiRjJQSVJBelVOZjg2MjVFTG1iOEdZZTZZRzlfbmt3dUdFQThVUXZYTUZURVhjU2hWVXNFMC1Ec0UtWVcyejJncXVaeW9nMk5CUjlpbmxESUQ2LW5uYmpUcms5MUV4OWM1RVEweEZWQ2VPM0Q2WXRPX242VmFZTWtzM3piTlRqQ2Nub19rUlV1VjFndWgyMDRpUQ?oc=5","date":"2025-01-27","type":"trial","source":"PR Newswire","summary":"Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSymposium™ 2025 - PR Newswire","headline":"Immusoft to Present Positive Data from the First Engineered B Cell in a Human Clinical Trial at the 21st Annual WorldSym","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPRkpRTlNZZ0ltM0RwY3pOaXI2WllPQWh3QjVra3lNbkxycE1mOVozbzExVHRjOTdwZ1VfWC03RUppa29LOXhFS0d0OG4wRE1hU3FjV0UyWFRPcWdQek9rUm4tVHVaaXVhSWNHLV9CTkppNV9Db3NWWncxbVR2QlFWYkFqTHFfb0JJYkRrYlFURC1YTy1NWkxlUTM1NG5UaVVtMU9KdF91b2EyX0M5bFFOWFc3SDlnOUZwRVJuWHJ3SzljS2Y4SUE5SC1hcjJPSkpkbWNxbEJ6ekh3WG9aUzZnejNtUjhndUluQUE?oc=5","date":"2024-09-23","type":"trial","source":"PR Newswire","summary":"Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial - PR Newswire","headline":"Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNTWJjTTlfNERud3JBNUZzVW1idl92el9vUThrR2NXM3lvdTloX2dRS3lwV21jTlBkR1NuYkNTZWVvdkFwY1BSVjFQeUNDYXpnWGFFYWh5S0thRElobE92bW01RVVPY3VlZ0NMaHVXVDByZ1BvSmE4YUQwTjZkRi1KTVplQ1JtUUgzVlBJcjhvNjA1czlpQW5kOUw3bkstMnBSdGZMQy13bnJpLXlPQzd4emV0Nk9FQQ?oc=5","date":"2021-10-13","type":"pipeline","source":"Fierce Biotech","summary":"Takeda bets up to $900M on Immusoft's cell therapies for neurometabolic disorders - Fierce Biotech","headline":"Takeda bets up to $900M on Immusoft's cell therapies for neurometabolic disorders","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}